4'-Methyl-α-pyrrolidinopropiophenone

From WikiMD.com Medical Encyclopedia

Synthetic stimulant drug


4'-Methyl-α-pyrrolidinopropiophenone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


4'-Methyl-α-pyrrolidinopropiophenone (also known as 4-MePPP) is a synthetic stimulant drug of the cathinone class. It is chemically related to α-pyrrolidinopropiophenone (α-PPP) and is known for its psychoactive effects.

Chemical Structure and Properties[edit | edit source]

Chemical structure of 4'-Methyl-α-pyrrolidinopropiophenone

4'-Methyl-α-pyrrolidinopropiophenone is a derivative of α-PPP, with a methyl group added to the para position of the phenyl ring. Its chemical formula is C14H19NO, and it has a molar mass of 217.31 g/mol. The compound features a pyrrolidine ring, which is a common structural motif in many synthetic stimulants.

Pharmacology[edit | edit source]

4-MePPP acts as a central nervous system stimulant. It is believed to exert its effects by increasing the levels of neurotransmitters such as dopamine and norepinephrine in the brain, similar to other stimulants in the cathinone class. This increase in neurotransmitter levels leads to enhanced alertness, energy, and euphoria.

Effects and Usage[edit | edit source]

The effects of 4-MePPP are similar to those of other synthetic stimulants, including increased heart rate, elevated blood pressure, and heightened alertness. Users may also experience euphoria, increased sociability, and decreased appetite. However, the use of 4-MePPP can also lead to adverse effects such as anxiety, paranoia, and cardiovascular issues.

Legal Status[edit | edit source]

The legal status of 4-MePPP varies by country. In some jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. In others, it may be unregulated, although this is subject to change as new legislation is enacted.

Safety and Toxicity[edit | edit source]

The safety profile of 4-MePPP is not well-established, and its use is associated with potential health risks. As with other synthetic stimulants, there is a risk of overdose, which can lead to severe cardiovascular and neurological complications. Long-term use may also result in dependence and withdrawal symptoms.

Related Compounds[edit | edit source]

4-MePPP is part of a broader class of synthetic stimulants known as substituted cathinones. Other related compounds include mephedrone, methylone, and MDPV. These substances share similar chemical structures and pharmacological effects.

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD